idarubicin has been researched along with Hemorrhagic Thrombocythemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bosi, A; Coltro, G; Guglielmelli, P; Mannelli, F; Pacilli, A; Vannucchi, AM | 1 |
| Mollee, PN; Rodwell, R; Taylor, D; Taylor, KM; Williams, B | 1 |
2 other study(ies) available for idarubicin and Hemorrhagic Thrombocythemia
| Article | Year |
|---|---|
A life-threatening ruxolitinib discontinuation syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Diagnosis, Differential; Disease Progression; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Janus Kinase 2; Leukemia, Myeloid, Acute; Middle Aged; Nitriles; Pneumonia; Protein Kinase Inhibitors; Pulmonary Embolism; Pyrazoles; Pyrimidines; Remission Induction; Respiratory Distress Syndrome; Substance Withdrawal Syndrome; Thrombocythemia, Essential; Tomography, X-Ray Computed | 2017 |
Long-term molecular remission in promyelocytic transformation of myeloproliferative disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytarabine; Daunorubicin; Disease Progression; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Polycythemia Vera; Preleukemia; Prognosis; Remission Induction; Thrombocythemia, Essential; Thrombophilia; Translocation, Genetic; Tretinoin | 1999 |